Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665253 | 0.93 | LMNA (0.86) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL7264283 | 0.77 | PKM (0.85) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL11900640 | 0.77 | TSHR (0.80) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL17767825 | 0.76 | PKM (0.62) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL14438984 | 0.76 | TSHR (0.61) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL8537283 | 0.76 | LMNA (0.61) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL8535478 | 0.73 | SMN1; SMN2 (0.61) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL6623601 | 0.72 | PIK3CB (0.81) | LMNATSHRALDH1A1NPSR1MAPK1 | |
| SCHEMBL28674470 | 0.72 | MAPK1 (0.58) | LMNATSHRPKMALDH1A1NPSR1 | |
| SCHEMBL2534195 | 0.71 | PKM (0.56) | LMNATSHRPKMALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| WO-2014025749-A2 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | NSUN3, TARBP1, TRDMT1 | LMNA 2145/4885TSHR 3789/4885PKM 4022/4885 |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | NSUN3, TARBP1, TRDMT1 | LMNA 2146/4885TSHR 3625/4885PKM 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.